News AB Science Deutsche Boerse AG

Equities

A8D

FR0010557264

Real-time Estimate Tradegate Other stock markets 04:02:30 2024-07-09 am EDT			5-day change	1st Jan Change
1.145 ^EUR	-1.97%		+7.56%	-69.42%

Jul. 08	CAC40: will end in the red, despite easing OAT rates	CF
Jul. 08	That's not so bad, is it?

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CAC40: will end in the red, despite easing OAT rates	Jul. 08	CF
That's not so bad, is it?	Jul. 08
AB Science: positive phase 2 data in Covid-19	Jul. 08	CF
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19	Jul. 08	GL
AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19	Jul. 08	AQ
AB Science Announces Positive Results of Its Phase 2 Study Evaluating Masitinib in Covid-19	Jul. 08	CI
AB Science: negative CHMP opinion for masitinib in ALS	Jun. 28	CF
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS	Jun. 28	GL
AB Science: share price falls on resumption of trading	Jun. 03	CF
AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS	May. 31	GL
Transcript : AB Science S.A. - Special Call	May. 30
AB Science: towards a negative opinion from the CHMP, listing suspended	May. 29	CF
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS	May. 29	GL
AB Science reports its revenues for the year 2023 and provides an update on its activities	May. 15	GL
AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	May. 15	CI
AB Science: European patent granted for masitinib	May. 13	CF
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036	May. 13	GL
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient	May. 07	GL
AB Science: upbeat after legal success	May. 03	CF
French Appeals Court Acquits AB Science CEO of Insider Trading Charges	May. 03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AB Science Deutsche Boerse AG

Equities

A8D

FR0010557264

Summary

Filters